Therapy Areas: Devices
Sang Jung Kim Named to Lysando Board of Directors
13 July 2022 - - Liechtenstein-based antimicrobial proteins specialist Lysando AG has appointed Sang Jung Kim as new member to the board of directors, the company said.

Kim has a biotech background and more than 30 years experiences in relevant commercial areas.

As director of Sales and Marketing at Amicogen, a manufacturer of technical enzymes and strategic partner to the Lysando AG, he is already familiar to Lysando.

Kim joined Amicogen in March 2021, within the division for Enzyme and Biopharmaceuticals, responsible for Sales and Marketing Management as well as Business Development. Previously, from 1992 to 2021, he was employed at Novozymes, a company for Biological Solutions.

During his career with Novozymes, he worked in the plant protection division, gained various experiences with enzymes in Technical Industries, Food, Feed and Bioenergy.

Kim was further responsible for Sales and active within several management positions in Korea and Asia Pacific, lastly as the country manager for South Korea. Kim graduated from Seoul National University and holds a degree in Agricultural Chemistry.

The board of directors officially added Sang Jung Kim on 1st February 2022.

Lysando AG is in for antimicrobial proteins, so-called Artilysins.

Artilysins are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly.

Artilysins can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.

The R and D Facility of Lysando AG is Lysando Innovations Lab GmbH located in BioPark in Regensburg. BioPark Regensburg promotes biotechnology, medical technology, diagnostics and analytics as well as the health economy of the Regensburg area.